Frontlight ResearchEarly access
CompletedPhase 3
IPAD Trial
Key facts
- Who runs it
- Universitair Medisch Centrum Utrecht
- Where
- Netherlands3 sites in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 100 people enrolled
- Started
- 12 Jul 2024
- Ended
- 31 Mar 2026
- Type of study
- Interventional
- Record updated
- 18 March 2026
Who can take part
- Age
- Up to 64 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age 8-60 years
- Diagnosis of Primary Antibody Deficiency / Common Variable Immunodeficiency Disorder (see Appendix I protocol)
- Indication for immunoglobulin replacement therapy and/or treated with immunoglobulin replacement therapy
- Current IgG dosing 0.25 - 0.6 gr / kg / 3-4 weeks
- Receiving treatment and follow-up for PAD by a physician in one of the participating centers
- Written informed consent
Who cannot take part
- Diagnosis of Combined Immunodeficiency (CID) disease at onset of study (see Appendix 1). Explanation: Combined Immunodeficiency is featured by the occurrence of more viral infections and reactivations and thus less comparable to PAD
- Severe pulmonary disease, determined by an independent radiologist: a. Baseline AD score > 7 and/or ILD score > 5, in combination with: i. Saccular bronchiectasis on CT scan, or; ii. Clinical diagnosis of severe respiratory insufficiency ( (defined as: saturations in room air <92%, and/ or oxygen dependency). b. Baseline pulmonary function (FEV1 and FVC) <70% expected for age and body weight / length)
- Active smoker
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To show the protective value and to measure cost effectiveness of higher Ig dosing on progression of lung disease in PAD.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Influencing Progression of Airway Disease in Primary Antibody Deficiency
- Record updated
- 18 March 2026